Title:Melatonin Inhibits the Malignant Progression of Glioblastoma via Regulating
miR-16-5p/PIM1
Volume: 19
Issue: 1
Author(s): Zhaoxian Yan, Xin Zhang, Lin Hua and Lifa Huang*
Affiliation:
- Department of Neurosurgery,
Zhejiang Provincial Hospital of Traditional Chinese Medicine, the First Affiliated Hospital of Zhejiang Chinese Medical
University, Hangzhou, China
Keywords:
Glioblastoma, melatonin, microRNA-16-5p, PIM1, malignant progression, in vivo experiments.
Abstract:
Objectives: Melatonin (MT) is a pineal hormone with antineoplastic potential. This study
aims to explore the therapeutic potential and mechanism of MT on glioblastoma (GBM).
Methods: A human GBM cell line, LN229, was used to evaluate the function of MT. Cell viability,
apoptosis, and migration were detected by CCK-8, flow cytometry, and transwell assays, respectively.
The mRNA and protein expressions of specific genes were measured by qRT-PCR and western
blot, respectively. The regulatory relationship between miR-16-5p and PIM1 was validated by dual
luciferase reporter gene assay. A mouse xenograft model was established to prove the anti-tumor
effect and related mechanisms of MT in vivo.
Results: MT inhibited the viability and migration and promoted the apoptosis of LN229 cells in a
dose-dependent manner. MiR-16-5p was dose-dependently up-regulated by MT in LN229 cells,
negatively regulating its target PIM1. MiR-16-5p inhibitor eliminated the anti-tumor effect of MT in
LN229 cells, while si-PIM1 reversed the effect of miR-16-5p inhibitor in MT-treated cells. MT
inhibited the tumor growth in vivo and MT-induced PIM1 down-regulation was reversed by miR-
16-5p inhibition in tumor tissues.
Conclusions: MT inhibits the malignant progression of GBM via regulating miR-16-5p-mediated
PIM1.
